Showing results (181-190 of 214) with videos related to

Sort By:
Pageof 22
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 11, 2026
Clinical Trial Results Provide the Rationale to Protect Dual HIV-specific T Cells with a Signaling-Defective HIV Fusion InhibitorPablo Tebas, Julie K Jadlowsky, Yuqi Zhou, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 2, 2021
Intact Human Immunodeficiency Virus (HIV) Reservoir Estimated by the Intact Proviral DNA Assay Correlates With Levels of Total and Integrated DNA in the Blood During Suppressive Antiretroviral TherapyEmmanouil Papasavvas, Livio Azzoni, Brian N Ross, et al.
Journal of Personalized Medicine|February 25, 2022
Preliminary Acceptability of a Home-Based Peripheral Blood Collection Device for Viral Load Testing in the Context of Analytical Treatment Interruptions in HIV Cure Trials: Results from a Nationwide Survey in the United StatesKarine Dubé, Shadi Eskaf, Elizabeth Hastie, et al.
Blood|December 25, 2012
Antiviral effects of autologous CD4 T cells genetically modified with a conditionally replicating lentiviral vector expressing long antisense to HIVPablo Tebas, David Stein, Gwendolyn Binder-Scholl, et al.
AIDS (London, England)|June 15, 2021
Frequency of post treatment control varies by antiretroviral therapy restart and viral load criteriaJesse Fajnzylber, Radwa Sharaf, John N Hutchinson, et al.
Open Forum Infectious Diseases|September 4, 2023
The Penn Medicine COVID-19 Therapeutics Committee-Reflections on a Model for Rapid Evidence Review and Dynamic Practice Recommendations During a Public Health EmergencyGeorge L Anesi, Kathleen Degnan, Lauren Dutcher, et al.
The Journal of Clinical Investigation|July 18, 2023
The latent reservoir of inducible, infectious HIV-1 does not decrease despite decades of antiretroviral therapyNatalie F McMyn, Joseph Varriale, Emily J Fray, et al.
Signal Transduction and Targeted Therapy|October 2, 2025
Retinol Binding Protein 4 reactivates latent HIV-1 by triggering canonical NF-κB, JAK/STAT5 and JNK signallingChiara Pastorio, Khumoekae Richard, Shariq Usmani, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 29, 2024
2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Management of COVID-19: Anti-SARS-CoV-2 Neutralizing Antibody Pemivibart for Pre-exposure ProphylaxisAdarsh Bhimraj, Yngve Falck-Ytter, Arthur Y Kim, et al.
The New England Journal of Medicine|July 22, 2015
Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1Susanna Naggie, Curtis Cooper, Michael Saag, et al.
Pageof 22